Trial Profile
A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI) in cystic fibrosis patients with pseudomonas aeruginosa lung infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2012
Price :
$35
*
At a glance
- Drugs Colistimethate sodium (Primary) ; Tobramycin
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Registrational; Therapeutic Use
- Acronyms Freedom
- Sponsors Forest Laboratories
- 11 Dec 2012 New trial record